A retrospective study for the diagnostic value of chromosomal microarray analysis in fetuses with high-risk prenatal indications
Open Access
- 25 August 2025
- journal article
- genetics
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1649253
Abstract
Objective: The aim of this study was to determine the diagnostic value of prenatal chromosomal microarray analysis (CMA) for fetuses at high risk for various conditions on chromosomal abnormalities.Methods: In the study, 8,560 clinical samples were collected from pregnant women between February 2018 and June 2022, including 75 villus, 7,642 amniotic fluid, and 843 umbilical cord blood samples. All samples were screening for chromosomal abnormalities using both CMA and karyotyping. This retrospective analysis included 8,560 pregnancies with high-risk indications for invasive prenatal diagnosis, mainly including ultrasound anomalies, high risk for maternal serum screening (MMS), high risk for non-invasive prenatal tests (NIPTs), family history of genetic disorders or birth defects, and advanced maternal age (AMA). All samples were evaluated using invasive CMA. The rate of clinically significant genomic imbalances between the different groups was compared.Results: The success rate of CMA was 99.95% (8,556/8,560). A total of 1,037 samples (12.11%, 1,037/8,560) were presented with chromosomal abnormalities using CMA, whereas 803 samples (9.38%, 803/8,560) were shown with chromosomal abnormalities using karyotyping. The overall prenatal diagnostic yield was 1,040 (12.14%) of 8,560 pregnancies. Clinically significant genomic aberrations were identified in 153 (6.21%) of 2,463 patients with non-structural ultrasound anomalies, 79 (6.38%) of 1,238 with structural ultrasound anomalies, 37 (4.26%) of 868 at high risk from MSS, 395 (42.29%) of 934 at high risk from NIPTs, 16 (2.94%) of 544 with a family history, 7 (1.89%) of 369 with AMA, 1 (1.56%) of 64 with a history of adverse exposure, 10 (4.46%) of 224 with parental chromosome anomaly, and 9 (2.99%) of 301 with other indications.Conclusion: CMA has a greater diagnostic value for screening chromosomal abnormalities, especially in pregnant women with normal karyotypes. The diagnostic yields of CMA for pregnancies with different indications greatly varied. CMA could serve as a first-tier test for structural anomalies, especially multiple anomalies, hydrops fetalis, cystic hygroma, and thickened nuchal translucency or nuchal fold.Keywords
This publication has 27 references indexed in Scilit:
- Prenatal chromosomal microarray analysis and karyotyping in fetuses with isolated choroid plexus cyst: A retrospective case-control studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2024
- Genetic profile of isolated congenital diaphragmatic hernia revealed by targeted next‐generation sequencingPrenatal Diagnosis, 2018
- Pregnant patients' risk perception of prenatal test results with uncertain fetal clinical significance: ultrasound versus advanced genetic testingPrenatal Diagnosis, 2015
- Xp21 deletion in female patients with intellectual disability: Two new cases and a review of the literatureEuropean Journal of Medical Genetics, 2015
- Risk of selected structural abnormalities in infants after increased nuchal translucency measurementAmerican Journal of Obstetrics and Gynecology, 2014
- Prenatal diagnosis of chromosomal mosaicism in over 1600 cases using array comparative genomic hybridization as a first line testPrenatal Diagnosis, 2014
- The clinical utility of microarray technologies applied to prenatal cytogenetics in the presence of a normal conventional karyotype: a review of the literaturePrenatal Diagnosis, 2013
- Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysisUltrasound in Obstetrics & Gynecology, 2013
- Cystic hygroma and lymphangioma: associated findings, perinatal outcome and prognostic factors in live-born infantsArchives of Gynecology and Obstetrics, 2007
- The second trimester genetic sonogramAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2007